The XPB Subunit of the TFIIH Complex Plays a Critical Role in HIV-1 Transcription, and XPB Inhibition by Spironolactone Prevents HIV-1 Reactivation from Latency

Luisa Mori, Katharine Jenike, Yang-Hui Jimmy Yeh, Benoît Lacombe, Chuan Li, Adam Getzler, Sonia Mediouni, Michael Cameron, Matthew Pipkin, Ya-Chi Ho, et al.

To cite this version:

Luisa Mori, Katharine Jenike, Yang-Hui Jimmy Yeh, Benoît Lacombe, Chuan Li, et al. The XPB Subunit of the TFIIH Complex Plays a Critical Role in HIV-1 Transcription, and XPB Inhibition by Spironolactone Prevents HIV-1 Reactivation from Latency. Journal of Virology, American Society for Microbiology, 2020, 95 (4), pp.e01247-20. 10.1128/jvi.01247-20. hal-03321338
The XPB subunit of the TFIIH complex plays a critical role in HIV-1 transcription and XPB inhibition by Spironolactone prevents HIV-1 reactivation from latency.

Luisa Mori\textsuperscript{a}, Katharine Jenike\textsuperscript{b}, Yang-Hui Jimmy Yeh\textsuperscript{b}, Benoît Lacombe\textsuperscript{c}, Chuan Li\textsuperscript{a}, Adam Getzler\textsuperscript{a}, Sonia Mediouni\textsuperscript{a}, Michael Cameron\textsuperscript{a}, Matthew Pipkin\textsuperscript{a}, Ya-Chi Ho\textsuperscript{b}, Bertha Cecilia Ramirez\textsuperscript{c}\textsuperscript{*}\textsuperscript{#}\textsuperscript{§}, and Susana Valente\textsuperscript{a}\textsuperscript{#}\textsuperscript{§}

\textsuperscript{a}The Scripps Research Institute, Department of Immunology and Microbiology, Jupiter, FL, USA

\textsuperscript{b}Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT, USA

\textsuperscript{c}Institut Cochin, Inserm, CNRS, Université Sorbonne Paris Cité, Paris, France.

*Current address: Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Université Paris-Sud, Université Paris-Saclay, Gif-sur-Yvette, Paris, France.

Running title: Spironolactone blocks HIV-1 reactivation from latency

#Address correspondence to Susana Valente, svalente@scripps.edu and to Bertha Cecilia Ramirez, cecilia.ramirez@i2bc.paris-saclay.fr

* K.J. and Y.-H.J.Y. contributed equally to this work

§ B.C.R. and S.V. contributed equally to this work

Word count: Abstract = 248 words, Importance = 150, Main Text = 6881 words
ABSTRACT

HIV transcription requires assembly of cellular transcription factors at the HIV-1 promoter. The TFIIH general transcription factor facilitates transcription initiation by opening the DNA strands around the transcription start site and phosphorylating the C-terminal domain for RNA polymerase II (RNAPII) for activation. Spironolactone (SP), an FDA approved aldosterone antagonist, triggers the proteasomal degradation of the XPB subunit of TFIIH, and concurrently suppresses acute HIV infection in vitro. Here we investigated SP as a possible block-and-lock agent for a functional cure aimed at the transcriptional silencing of the viral reservoir. The long-term activity of SP was investigated in primary and cell line models of HIV-1 latency and reactivation. We show that SP rapidly inhibits HIV-1 transcription by reducing RNAPII recruitment to the HIV-1 genome. shRNA knockdown of XPB confirmed XPB degradation as the mechanism of action. Unfortunately, long-term pre-treatment with SP does not result in epigenetic suppression of HIV upon SP treatment interruption, since virus rapidly rebounds when XPB reemerges; however, SP alone without ART maintains the transcriptional suppression. Importantly, SP inhibits HIV reactivation from latency in both cell line models and resting CD4+ T cells isolated from aviremic infected individuals upon cell stimulation with latency reversing agents. Furthermore, long-term treatment with concentrations of SP that potently degrade XPB does not lead to global dysregulation of cellular mRNA expression. Overall, these results suggest that XPB plays a key role in HIV transcriptional regulation and XPB degradation by SP strengthens the potential of HIV transcriptional inhibitors in block-and-lock HIV cure approaches.
IMPORTANCE

Antiretroviral therapy (ART) effectively reduces an individual’s HIV loads to below the detection limit, nevertheless rapid viral rebound immediately ensues upon treatment interruption. Furthermore, virally suppressed individuals experience chronic immune activation from ongoing low-level virus expression. Thus, the importance of identifying novel therapeutics to explore in block-and-lock HIV functional cure approaches, aimed at the transcriptional and epigenetic silencing of the viral reservoir to block reactivation from latency. We investigated the potential of repurposing the FDA-approved spironolactone (SP), as one such drug. SP treatment rapidly degrades a host transcription factor subunit, XPB, inhibiting HIV transcription and blocking reactivation from latency. Long-term SP treatment does not affect cellular viability, cell cycle progression or global cellular transcription. SP alone blocks HIV transcription in the absence of ART but does not delay rebound upon drug removal as XPB rapidly reemerges. This study highlights XPB as a novel drug target in block-and-lock therapeutic approaches.
INTRODUCTION

Upon HIV-1 integration into the host genome the provirus becomes transcriptionally silent as the cell returns to a quiescent state (1). Despite effective antiretroviral therapy (ART) that suppresses HIV-1 replication to below the detection limit, these latent proviruses can reinitiate viral production upon cell stimulation or treatment interruption (2–4). The total elimination of this latent reservoir has become a major goal of HIV-1 eradication strategies and interventions involving latency modifying agents, immune therapies, or gene and cell-based therapies are being investigated (5–7). More recently though, HIV-1 remission or a functional cure have been explored (8, 9). A functional cure entails either null or sufficiently low viral replication that is controlled by the immune system in the absence of ART, while proviral DNA remains detectable. This would allow the prospect of functionally cured individuals maintaining undetectable viral loads in the absence of ART, without risk of onward transmission and no ongoing immunological damage that is associated with HIV infection (10–12). One such functional cure approach has been branded the block-and-lock approach, which aims at the transcriptional silencing of the viral reservoir (5). There are unfortunately no clinically available HIV-1 specific transcriptional inhibitors.

Transcription at the HIV-1 promoter begins with the assembly of the pre-initiation complex (PIC). The 5' long terminal repeat (LTR), which serves as the viral promoter, contains binding sites for multiple transcription factors (TFs) which bind sequentially to form the PIC. These include NF-κB, Sp1, TATA-binding protein (TBP) (as part of the general transcription factor TFIID), TFIIA, TFIIB and TFIIF, which together direct RNA polymerase II (RNAPII) binding to form a stable promoter complex (13–15). The PIC is
completed by the addition of the TFIIE heterodimer and TFIIH (15). TFIIH is a ten-protein complex consisting of a core (XPB, XPD, p62, p52, p44, p34 and p8) and cyclin-dependent kinase (CDK)-activating kinase (CAK) subcomplex (CDK7, Cyclin H and MAT1) (16). TFIIH plays a crucial role in the initiation of transcription, but also in nucleotide excision repair, where bulky adducts are removed from damaged DNA (17).

In transcription, once the PIC has assembled, the XPB subunit functions as a DNA translocase, feeding the DNA into the RNAPII cleft, introducing negative supercoiling and initiating the formation of the transcription bubble (16, 18, 19). The CDK7 subunit is responsible for the initial activating phosphorylation of serine 5 in the heptapeptide repeats on the RNAPII (CTD) tail (pSer5) (20–22). Activated RNAPII clears the promoter, but rapidly stalls after transcribing the first ~59 nucleotides downstream of the transcription start site (TSS), which comprises a secondary structure termed the transactivation response element (TAR) (23). RNAPII stalls for a few reasons, namely its association with negative elongation factors, NELF and DSIF, as well as the presence of Nucleosome-1 (Nuc-1) downstream from the TSS that occlude efficient elongation (24–26). The high affinity interaction of the viral protein Tat, which is produced from rare full-length transcripts, with the TAR RNA allows recruitment of the positive elongation factor, P-TEFb, consisting of CyclinT1 and CDK9 (24, 25, 27–33). CDK9 phosphorylation of NELF (leading to detachment from RNAPII), DSIF (converts to an elongation factor), as well as Ser2 on the RNAPII CTD allows transcription to proceed (34, 35). Tat plays a fundamental role in HIV transcription and is key for the rapid and robust increase in full-length viral transcripts from the HIV genome upon reactivation from latency (28, 36–39). The proof-of-concept for the block-and-lock
approach was shown with the small molecule inhibitor of Tat, didehydro cortistatin A (dCA) in CD4+ T cells isolated from infected individuals and in the humanized mouse model of HIV latency (40–42). dCA directly interacts with the basic domain of Tat, blocking the interaction of Tat with TAR and preventing transcriptional elongation (40). As such, the long-term treatment of cells with dCA restricts RNAPII recruitment to the promoter and over time epigenetic marks are deposited at the HIV-1 promoter, promoting silencing and blocking reactivation from latency (41, 43, 44).

In search for novel molecules that regulate HIV transcription to increase our portfolio of block-and-lock approaches, we studied the action of spironolactone (SP). SP is a potassium-sparing diuretic, an aldosterone antagonist that blocks binding to the mineralocorticoid receptor (MR), and has been approved since 1959 for the treatment of a range of conditions, including hypertension and heart failure (45). An off-target effect of SP is the proteasomal degradation of the ATP-dependent helicase, XPB subunit of the transcription factor TFIIH complex (46–49). XPB degradation is dependent on the 26S proteasome and ubiquitinating enzymes (46). SP triggers XPB Ser90 phosphorylation by the CDK7 subunit of TFIIH leading to SCF^{FBXL18} E3 ligase-mediated ubiquitination and proteasomal degradation (50). Despite XPB’s critical role in transcription initiation (14, 16), its degradation was reported not to affect global transcription (51, 52). However, subsequent studies showed transcriptional inhibition of genes highly dependent on NF-κB (47, 51). The two binding sites for NF-κB at the HIV-1 LTR allow NF-κB control of HIV-1 reemergence from latency (53). Lacombe et al. previously demonstrated that XPB degradation, by short-term treatment of cells with SP inhibits acute HIV-1 and HIV-2 transcription (48).
Here, we explored the potential of SP as a block-and-lock agent, through long-term treatment of latently infected cells and resting CD4+ T cells explanted from infected individuals. We demonstrated the ability of SP to inhibit HIV-1 transcription in latently infected cells and suppress reactivation from latency by potent LRAs, which correlated with loss of RNAPII recruitment to the HIV-1 promoter and genome, without damaging cellular effects. We confirmed the activity of SP was mediated by XPB via knockdown studies and is independent of the Tat-TAR interaction. Altogether, our results suggest that XPB plays a key role in HIV-1 transcriptional activation and its inhibition by SP blocks HIV-1 expression.

RESULTS

Treatment of latently infected cell lines with SP inhibits transcription of HIV-1.

SP has been previously shown to block acute HIV infection of CD4+ T cells (48). Here to explore whether SP could be used in block-and-lock approaches to an HIV cure we investigated its ability to inhibit transcription from cell line models of latency. We studied SP activity in two established cell line models of latency, OM-10.1 and ACH-2 cells, in the presence of ART. OM-10.1 cells are a promyelocytic line derived from HL-60 cells that survived an acute HIV-1 infection. Each cell contains a single integrated, full length provirus (54). SP treatment of these cells resulted in a dose-dependent reduction of HIV-1 capsid p24 in the supernatant, with an IC50 of 1.77 μM (Fig. 1A). This inhibition correlated with a dose-dependent degradation of the cellular protein XPB (Fig. 1B). Eplerenone (EPL), a more selective mineralocorticoid receptor (MR) antagonist analog of SP, does not lead to XPB degradation (46, 47, 51, 55). As previously reported
(48), no inhibition of HIV-1 was observed with increasing concentrations of EPL (Fig. 1C), suggesting the mechanism of HIV-1 inhibition is independent of MR antagonism. No cytotoxicity was observed with up to 50 µM SP or EPL following a 72 h incubation (Fig. 1D).

Next, we evaluated the long-term effects of SP treatment. OM-10.1 cells were treated with 10 µM SP, 10 µM EPL or DMSO for 190 days (Fig. 1E), and capsid p24 released into the supernatant was quantified by p24 ELISA. In OM-10.1 cells, SP rapidly inhibits viral production by approximately 2.5 logs, with capsid p24 levels stabilizing around the limit of detection (3 pg/ml). As expected, a reduction in the HIV-1 mRNA expression was observed in parallel (Fig. 1F, red line). The mRNA levels of the XPB gene, ERCC3, where either unaffected or slightly elevated by SP treatment (Fig. 1F, brown line). This confirms previous reports that degradation of XPB by SP is mediated by the 26S proteasome and not by reduced XPB mRNA expression (46). Of note, the half-life of SP in long-term culture of OM-10.1 cells with ART was determined by LC-MS/MS to be 2.3 (+/- 0.2) days and cells were split and treated every three days. All experiments were performed in the presence of ART unless otherwise stated. Of note, without ART the half-life is 2.9 (+/- 1.7) days. Altogether these results suggest that, in OM-10.1 cells, SP treatment combined with ART over time inhibits HIV-1 transcription to very low, frequently undetectable levels without obvious cytotoxic effects in the cells.

We next assessed the activity of SP in the ACH-2 cell line, a T cell clone containing a single integrated provirus (56, 57), which harbors a C37T mutation TAR such that the Tat-TAR feedback loop is defective resulting in low transcription rates (58, 59). SP treatment of these cells resulted in a similar dose-dependent reduction of HIV-1
capsid p24 in the supernatant, with an IC_{50} of 1.95 \mu M (Fig. 2A), which correlated with a
dose-dependent degradation of XPB (Fig. 2B). Again, EPL was inactive against HIV
(Fig. 2C). Cytotoxicity was not observed up to 20 \mu M of SP for a 72 h period, nor up to
50 \mu M with EPL (Fig. 2D). The long-term treatment of ACH-2 cells inhibited viral
production by 1-1.5 logs, with capsid production stabilizing around 20-100 pg/ml (Fig.
2E). As expected, a reduction in cell associated HIV RNA was also observed (Fig. 2E),
while levels of XPB mRNA were either unaffected or slightly elevated (Fig. 2F). No
difference in cell viability or cell number was observed over time (Figure 2G).
Differences in the magnitude of SP activity on HIV-1 p24 production between OM-10.1
and ACH-2 cells may be related to the level of XPB degradation in these cell lines, 95%
in OM-10.1 cells as compared to 81% in ACH-2 cells (Fig. 1B and 2B). Given that SP
inhibits the transcription from proviruses with an incompetent Tat-TAR feedback loop,
as is the case of ACH-2 cells, the mechanism of action of SP is likely independent of the
Tat-TAR interaction.

We also investigated the potential of SP to inhibit SIV_{mac239} in HUT-78 cells.
Potent suppression of SIV replication with SP, but not EPL or DMSO was observed over
a period of 12 days (Fig. 2G). This was accompanied by degradation of XPB by SP
treatment as measured by Western blot on day 12 (Fig. 2H, inset panel). A rapid decline
in cellular viability, due to cytotoxic effects of virus replication, was observed in DMSO
and EPL treated cells where virus replication was allowed to proceed, whilst the viability
of cells treated with 10 \mu M SP was not adversely affected (Fig. 2I). These results
suggest that SP may be used in latency studies in non-human primates infected with
SIV.
In sum, these results suggest that SP inhibits HIV-1 transcription in established cell line models of latency.

**RNA silencing of the XPB gene inhibits HIV-1 transcription.**

To confirm that HIV-1 inhibition by SP was truly dependent on XPB degradation, and not the result of an off-target effect, we knocked down the XPB gene, *ERCC3*, by shRNA and assessed viral replication. OM-10.1 cells were transduced with a lentiviral vector carrying either an *ERCC3* specific shRNA or an shRNA targeting the GFP gene as control (since these cells do not contain GFP). In parallel, cells transduced with shGFP were treated with the IC$_{50}$ = 1.8 µM and IC$_{90}$ = 6.3 µM concentrations of SP, as well as 10 µM SP, to compare XPB levels and HIV replication. After 48 h of culture, cells were placed back on ART and selected with puromycin to enrich for cells containing the shRNA. After 10 days of puromycin selection, HIV-1 capsid production in the supernatant was measured by p24 ELISA, and cells were collected for RNA and Western blot analysis.

A knockdown efficiency of 70-80% at both the protein and RNA level (Fig. 3A-B) was achieved with the shRNA targeting *ERCC3*, while well tolerated by cells (Fig. 3C). Notably, SP treatment resulted in a slight upregulation of *ERCC3* mRNA (Fig. 3B), as previously observed (Fig. 1F), which we suspect is a cellular compensatory mechanism for the loss of XPB protein. When compared to cells transduced with the shGFP control, the *ERCC3* knockdown resulted in suppression of HIV *gag* mRNA and p24 production to levels between the IC$_{50}$ and IC$_{90}$ concentrations of SP (Fig. 3D-E).
Importantly, when we compared expression of additional TFIIH components, we observed substantial downregulation of XPD, CDK7 and cyclin H with SP treatment (Fig. 3F). With ERCC3 knock down, despite XPB downregulation similar to the IC₅₀ and IC₉₀ concentrations of SP, XPD was not downregulated (Fig. 3F). However, although not to the same degree as SP, a loss of CDK7 and Cyclin H were still detected (Fig. 3F).

Altogether our results strongly support that the inhibition of HIV-1 transcription observed with SP treatment is the result of XPB degradation.

Treatment of latently infected cells with SP reduces HIV-1 reactivation from latency.

We next investigated whether SP treatment could block the reactivation of latent HIV-1 proviruses when cells were exposed to LRAs. The specific LRAs and doses chosen to reactivate each cell model were selected based on the ability to potently stimulate HIV-1 replication, with minimal toxicity. Prostratin, phorbol myristate acetate (PMA) and TNF-α activate transcription by induction of NF-κB, while the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) promotes chromatin acetylation, namely at nucleosome-1 on the HIV-1 LTR (60–63).

OM-10.1 and ACH-2 cells were treated for 90 and 15 days, respectively, with 10 μM SP or DMSO and the levels of HIV-1 capsid production were monitored over time by p24 ELISA (Fig 4A-B). Cell number and viability remained stable over time (as in Figure 1 and 2). Once HIV levels had stabilized at maximal inhibition, the cells were treated with a panel of LRAs in the presence of ART and either 10 μM SP or DMSO. After an 8
h incubation period cells were collected and viral transcription assessed by RT-qPCR to
HIV nef mRNA. Robust reactivation was observed in DMSO+ART treated OM-10.1 and
ACH-2 cells (Fig. 4C-D, blue bars) with all LRAs tested. While some reactivation of HIV
in SP treated OM-10.1 and ACH-2 cells was observed in the presence of LRAs, these
were non-statistically significant (Fig. 6C-D, red bars). Similar results were observed in
the Jurkat latency models (J-Lat A1 and A2) (data not shown).

Next, we assessed the activity of SP in primary cells from ART-adherent
individuals living with HIV. Resting CD4+ T cells were isolated from peripheral blood
mononuclear cells (PBMCs) from seven individuals with undetectable HIV viral loads,
adherent to ART for at least one year with no viral load “blips” in the last six months.
These cells were treated for 24 h with either 10 µM SP or vehicle only in the presence of
the entry inhibitor T20, to prevent novel infections. In the final 6 h of treatment, cells
were challenged with PMA/ionomycin for T cell activation. SP treatment reduced HIV-1
reactivation an average of 1.4 log (27.6-fold) measured by RT-qPCR per million cells
(Fig. 4E). The expression of a housekeeping gene POLR2A was also measured and
showed modest, yet significantly increased levels (an average of 0.4 log, 2.5-fold) (Fig.
4F) (64). In sum, this demonstrates that SP inhibits reactivation from latency in primary
CD4+ T cells explanted from virally suppressed individuals.

In sum, these results show that treatment of latently infected cell lines, and ex
vivo stimulated primary CD4+T cells, with 10 µM SP dramatically reduces reactivation of
HIV-1 from latency when exposed to potent LRAs.
SP treatment alone blocks viral reactivation; however, long-term SP treatment does not prevent viral rebound upon treatment interruption. The long-term treatment of HIV-1 infected cells with the Tat inhibitor dCA results in the accumulation of epigenetic marks at the HIV-1 promoter, that render reactivation from latency very difficult to occur upon treatment interruption or stimulation with LRAs (41, 43, 44). Thus, we investigated whether SP treatment over time would lead to similar effects. First, we tested whether 10 µM SP alone was sufficient to maintain HIV transcription suppression in the absence of ART. As such, we washed off ART on day 69 from the OM-10.1 cell culture (three independent experiments) and measured viral p24 production in the supernatant (Fig. 5A, black arrows). A non-significant increase in HIV p24 production was observed in DMSO treated cells in the absence of ART (Fig. 8A, light blue line), while no such increase was observed in SP treated cells (Fig. 5A, orange line), suggesting SP treatment alone is able to block HIV replication in the absence of ART. Next, we assessed whether pre-treatment with SP would delay HIV rebound upon all treatment interruption, as such on day 78, DMSO and SP were washed off and cells maintained on ART alone (Fig. 5B, black arrow). As expected, HIV p24 levels remained stable in cells pre-treated with DMSO; however, within 12 days a rapid increase in virus replication back to DMSO levels was observed in cells pre-treated with SP (Fig. 8B orange line). Concomitantly, within 3 days of treatment interruption, we observed a rapid rebound in XPB protein levels, as well as other TFIIH components (XPD, CDK7 and Cyclin H) (Fig. 8C). In fact, XPB levels rebounded above the level of the DMSO control and remained elevated for at least 9 days post treatment interruption (Fig. 8C, orange lanes vs light blue lanes).
While pre-treatment with SP did not result in long-lasting epigenetic control of viral transcription upon treatment interruption, SP treatment alone seems sufficient to maintain HIV transcriptional inhibition in the absence of ART. These important results suggest that SP blocks HIV transcription as a single-therapy and holds great potential to be used in combination with other latency-promoting agents (LPAs), with the goal of establishing an epigenetic lock on the HIV genome.

**SP treatment reduces RNAPII recruitment to the HIV-1 genome.**

To confirm that transcriptional inhibition is the mechanism of action of SP against HIV, we investigated RNAPII recruitment to the HIV-1 genome. As such, we performed chromatin immunoprecipitation (ChIP) to RNAPII followed by RT-qPCR using primers recognizing the HIV-1 genome. We sought to identify differences in occupancy of total as well as phosphorylated Ser5 or Ser2 RNAPII (pSer5, pSer2 RNAPII).

Three independent long-term treatments (~70 days) of OM-10.1 cells with DMSO+ART or SP+ART (see Fig. 4A) were treated or not with 1 μM prostratin for 8 h, resulting in mean 4.3-fold increase in p24 production and a mean 147-fold increase in HIV mRNA (data not shown) in DMSO+ART treated cells, with no detectable changes in p24 production in SP treated cells observed (but a mean 5.3-fold increase in HIV mRNA) (data not shown). These cells were crosslinked and prepared for RNAPII ChIP. Without prostratin, with or without SP, a small peak of RNAPII was observed at the HIV promoter, with very little occupancy throughout the genome (Fig. 6A). Modest reductions in occupancy of total, pSer5 and pSer2 RNAPII in unstimulated SP+ART treated cells were observed compared DMSO+ART control (Fig. 6B-C, red vs dark blue.
Stimulation with prostratin led to a significant increase of total RNAPII occupancy in DMSO+ART treated cells, with a peak at the promoter and substantial occupancy throughout the genome (Fig. 6A, light blue line). As expected, a strong peak of pSer5 RNAPII was observed at the HIV promoter in DMSO+ART treated cells stimulated with prostratin, with a slight reduction in the gene body (Fig. 6B, light blue line). A peak of pSer2 RNAPII was observed at the HIV promoter of DMSO+ART treated cells stimulated with prostratin, drastically decreasing between nt positions 1000 and 3500, but increasing again towards the 3' end between positions 6000 and 9000 (Fig. 6C, light blue line). This is consistent with the role of pSer2 in relief of promoter-proximal pausing (mediated by P-TEFb (65, 66)) and recruitment of splicing and RNA processing machinery (mediated by CDK13/12 (66–69)). A significant reduction of RNAPII occupancy (total, pSer5 and pSer2) was observed on the HIV genome when prostratin reactivation was performed in the presence of SP (Fig. 6A-C, orange lines). This is apparent at the HIV promoter, but most noticeable along the gene body. Almost no pSer5 RNAPII is observed along the HIV genome beyond the promoter in SP treated cells, while total and pSer2 RNAPII is still detected at the both the promoter and towards the 3'end of the genome. Importantly, no significant differences were observed in the occupancy of RNAPII (Total, pSer5, pSer2) on the promoter of GAPDH or in the gene body of RPL13A (Fig. 6D-F).

In sum, these results indicate that long-term treatment of cells with 10 µM SP significantly reduce RNAPII occupancy on the HIV genome, and potently suppresses RNAPII recruitment upon prostratin stimulation. These effects are not observed on the promoter or ORF of housekeeping genes.
Long-term effects of SP treatment on the cellular transcription apparatus and cell cycle progression.

Previous reports have suggested that short term treatment of cells with 10 µM SP selectively degrades the XPB subunit of TFIIH, leaving other components mostly unaffected (46, 48). Additionally in short-term studies, using RNA-seq and uridine analog 5-ethynyluridine (EU) incorporation assays Alekseev et al did not observe global transcriptional defects in SP treated cells (51). We thus investigated the long-term effects of SP treatment on components of the TFIIH complex, as well as on a few important CDKs and respective cyclins. No significant differences were observed in the mRNA expression of any of the TFIIH components in OM-10.1 cells treated with SP for over 100 days (Fig. 7A, cells from 1D). However, at the protein level, although XPB was by far the most downregulated protein (over 95%), a clear downregulation of other components of TFIIH (namely XPD, p62, CDK7 and Cyclin H) was observed at all time points, as compared to DMSO and EPL (Fig. 7B). In addition, in ACH-2 cells treated for 15 days with 10 µM SP, a similar, but more modest reduction in XPD, Cyclin H and CDK7 subunits of TFIIH was also observed (Fig. 7C). This downregulation of TFIIH components was detected as early as 72 h after treatment of OM-10.1 cells with 10 µM SP and did not appear to magnify over time (Fig. 7D).

We also investigated whether long-term SP treatment affected the expression and function of other critical CDKs and their Cyclin partners, such as P-TEFb (CDK9 and Cyclin T1) and cell cycle proteins CDK2, Cyclin E1 and Cyclin A. No significant differences were observed between SP, vehicle or EPL treated OM-10.1 cells (Fig. 7B).
Recently, CDK7 was shown to be the primary kinase responsible for CDK9 Ser175 phosphorylation, thought to bias CDK9's binding from BRD4 to Tat (30). Additionally, it was proposed that CDK7 phosphorylates CDK9 at Thr186, which is required for CDK9 activity, though CDK9 also autophosphorylates at this residue (30, 70). Given SP reduction of CDK7 protein expression (Fig. 7B,D), we compared the levels of pThr186 and pSer175 CDK9 by Western blot in SP and vehicle treated OM-10.1 cells treated for 24 days (Fig. 7E). While potent depletion of XPB and approximately 60% reduction in CDK7 was observed, the levels of total, pThr186 and pSer175 CDK9 remained unchanged. Furthermore, by propidium iodide staining, no differences in cell cycle progression between treatment groups were observed (Fig. 7F).

In sum, although long-term treatment of cells with 10 µM SP results in a reduction in protein levels of additional components of the TFIIH complex besides XPB, we did not observe differences in the expression of other important kinases, cyclins, housekeeping genes, phosphorylation of CDK9 nor in cell cycle progression.

**Treatment of latently infected cells with SP reduces HIV transcription without global dysregulation of cellular mRNA expression.**

Due to the critical nature of TFIIH for RNAPII-mediated transcription, and the significant loss of some of the components of TFIIH, in addition to XPB (Fig. 3F, 6C, 7), we investigated global cellular mRNA synthesis defects that may occur with SP treatment. As such, we treated OM-10.1 cells for 15 days with either SP+ART or DMSO+ART (once maximal HIV inhibition had been achieved in the SP treated cells), followed by RNA extraction and mRNA-seq analysis. For this study, we included cells...
stimulated or not with the PKC agonist, prostratin, to assess effects on activation
dependent genes. HIV encoding genes were among the most significantly
downregulated genes in cells treated with SP compared to DMSO control, particularly
upon stimulation with prostratin (Fig. 8A, left and right panels, red points). Some of the
most significantly affected cellular genes are highlighted and labelled in blue [pAdj<1e-10
and abs(log2FoldChange)>1 for SP vs DMSO comparisons (left and right panels,
Supplemental Tables S1-S2), and padj<1e-30 with an abs(log2FoldChange)>2.5 for
Stim vs No stim comparisons (middle two panels, Supplemental Tables S3-S4)]. In
unstimulated cells, treatment with SP resulted in the upregulation of 49 genes and
downregulation of 25 as compared to DMSO control (Fig. 8A left panel, pAdj <= 0.05,
log2FC >= abs(1)). Prostratin stimulation led to the differential expression of 758 genes
in DMSO treated cells and 823 genes in SP treated cells (546 of which were
differentially expressed between conditions) (Fig. 8A, middle panels). SP treatment,
while specifically affecting the expression of some genes, does not appear to affect all
RNAPII-mediated transcription, in support of previous studies suggesting XPB depletion
by SP does not affect global cellular transcription (51). To determine more rigorously
what patterns of gene signaling pathways were affected by SP treatment, we performed
gene set enrichment analysis (GSEA) (71). A bubble-lattice plot was constructed to
highlight gene sets affected by SP treatment, where the color of the bubble represents
the normalized enrichment score (NES) (indicating the number and differential intensity
of the assessed genes in each indicated pathway) and statistical significance is
indicated by the size of the bubble (Fig. 8B). HIV encoded genes were significantly
down-regulated as compared to DMSO control, particularly under conditions of
prostratin stimulation, indicating the strong specific effect of SP treatment on HIV transcription (Fig. 8B). Of note, with this type of bubble representation of the data, it is important to keep in mind the size of the gene set, for instance the MYC targets have modest downregulation with SP treatment, but since there are 200 genes in this set the NES score is high. On the other hand, downregulation of HIV genes is greater, but because there are lot fewer genes in this set the NES is smaller. Genes related to DNA packaging (histone and chromatin-related genes) were significantly upregulated in both unstimulated and prostratin stimulated SP treated cells (Fig. 8B). Conversely, MYC targets, E2F targets, and Type I IFN receptor binding genes were downregulated with SP treatment, which increased in significance upon prostratin stimulation (Fig. 8B).

Furthermore, cellular (endogenous) genes involved in the late phases of the HIV life cycle (reactome gene sets (72)) were modestly downregulated upon stimulation, which include genes involved in transcription, RNA processing and export from the nucleus (Fig. 8B). IFN-\( \gamma \) response genes were slightly upregulated in unstimulated SP treated cells, gaining significance upon stimulation (Fig. 8B). Other gene sets related to transcription of the HIV genome, RNAPII transcription of snRNAs, RNAPII elongation, IFN-\( \alpha \) response, housekeeping and apoptosis were not substantially affected (Fig. 8B).

Heatmaps were constructed from transcripts per million (TPM) data to facilitate direct comparison of gene expression with different lengths (Fig. 8C, Supplemental Table S5).

All HIV genes were clearly downregulated upon SP treatment and, although prostratin stimulation increased HIV expression, this was substantially reduced compared to DMSO treated cells (Fig. 8C, left panel). Because of the modest downregulation in genes involved in the late phase of the HIV life cycle observed in the GSEA (Fig. 8B),
we examined the expression of individual genes within this set. Expression of transcription related genes such as TFIIH, P-TEFb, the SEC, NELF, DSIF and RNAPII genes do not appear to be substantially affected by SP treatment (Fig. 8D, left panel). Furthermore, no obvious differences in expression of RNA splicing, export, capping or cleavage genes between SP and DMSO treated cells (Fig. 8C middle panel). These results are consistent with previous results, in which SP did not affect the transcriptional machinery and cell cycle progression (Fig. 7), but blocked HIV reactivation (Fig. 4). Nonetheless, SP treatment does curiously seem to upregulate a large subset of DNA packaging complex genes (Fig. 8C, right panel), which is often associated with defects in cell cycle progression (73). However, this upregulation might not be biologically significant since, as mentioned above, no obvious differences in cell division were observed in SP treated cells (Fig. 7).

In sum, SP treatment results in robust suppression of HIV transcripts both in unstimulated or prostratin stimulated cells, consistent with the observations in Figs.1-5. While the expression of a few specific gene sets were significantly impacted by SP treatment, we hypothesize that their fold change may not be biologically significant since we observe no major defects were observed in cell growth and viability. Nevertheless, the effects of SP treatment at concentrations sufficient to potently degrade SP will need to be assessed in vivo.

**DISCUSSION**

Inhibiting transcription from latent proviruses is an increasingly attractive approach for a functional cure for HIV-1. The long-term transcriptional inhibition of HIV-1 may lead to a
sustained epigenetic repression with the potential to contain viral transcription even in the absence of ART (43, 44). In addition, such transcriptional inhibition may reduce "blips", or moments of detectable viremia observed in some virally suppressed patients, as well as chronic immune activation that stems from the continuing trickling of HIV transcription and viral protein production observed under suppressive ART. To date, there are unfortunately no FDA approved HIV-1 transcriptional inhibitors available. In this study, we investigated the potential of the clinically approved drug SP, which targets the host transcription factor XPB for proteasomal degradation, for the inhibition of latent HIV-1 in various cell line models and primary CD4+ T cells from virally suppressed individuals.

In agreement with previous studies, we observed a dose-dependent reduction of XPB protein levels with SP treatment (Fig. 1B and 2B) (46–48, 51), which parallels a dose-dependent reduction in HIV-1 replication (Fig. 1A and 2A). Here we showed that specific shRNA knockdown of XPB resulted in similar HIV inhibition, suggesting that HIV inhibition by SP treatment is specifically mediated by XPB protein levels (Fig. 3). Importantly, EPL, a more specific MR antagonist, does not inhibit HIV nor degrades XPB (Fig. 1C and 2C). Thus, HIV inhibition by SP is independent of MR antagonism and dependent on the degradation of the host helicase XPB. Contrary to previous reports that showed short term SP treatments selectively degrade XPB, leaving other subunits of TFIIH relatively intact (47, 48, 51), we show that even after a short 72 h period the levels of XPD, p62, CDK7 and Cyclin H, but not other cellular proteins, were significantly reduced (Fig. 3F, 5C and 7). These effects seem to be somewhat cell type specific, since they were more pronounced in OM-10.1 as compared to ACH-2 cells.
This could be explained either by more modest XPB degradation in ACH-2 cells (Fig. 1B vs 2B) or it could be related to the absence of a functional Tat-TAR feedback loop in ACH-2 cells and this warrants further investigation. It remains to be determined whether loss of other TFIIH subunits is due to destabilization of the complex or to off-target proteasomal degradation. Of note, shRNA knockdown of the XPB gene, ERCC3, does not result in the same degree of TFIIH components loss (Fig. 3F). While reduction of XPB with ERCC3 shRNA knockdown was around that observed with 1.8 µM SP treatment, we do not observe any loss of XPD, and a more modest loss of CDK7 and Cyclin H. Importantly, ERCC3 knockdown showed no cytotoxic or cytostatic effects (Fig. 5C). Although shRNA knockdown of XPB resulted in an ~80% reduction of XPB protein (similar to treatment with 1.8 µM SP, Fig. 3A), with less effects on other TFIIH components, it reduced HIV mRNA levels to a greater degree than 1.8 µM SP treatment, further suggesting that development of more specific XPB degraders may improve on SP potency and could potentially avoid unwanted off-target transcriptional activity as well as the other known effects of SP on the MR.

Treatment of latently infected cells with SP results in a rapid, robust suppression of HIV transcription, and reactivation using LRAs is significantly inhibited (Fig. 4). Importantly, SP treatment blocks the strong HIV-1 reactivation by PMA/ionomycin in CD4+ T cells explanted from HIV-infected virally suppressed individuals (Fig. 4E). While levels of HIV reactivation were substantially reduced with SP treatment (average of 27.6-fold), the levels of the housekeeping gene, POLR2A (encoding a subunit of RNAPII), were modestly elevated (average of 2.5-fold) (Fig.4F). The slight increase in POLR2A
observed in primary cells upon SP treatment requires further investigation to determine whether this is a direct consequence of SP activity or is related to inhibition of HIV transcription. Of note, even if not statistically significant (p=0.78), the mRNA-seq analysis in OM-10.1 cells showed a slight increase in POLR2A expression in cells treated with SP stimulated with prostratin, as compared to DMSO (log2FC of 0.5). Furthermore, there were no obvious changes in expression of other RNAPII subunits (Fig. 8D, middle panel).

Importantly, SP treatment was shown to be sufficient to maintain HIV p24 production below the limit of detection in the absence of ART (Fig. 5A). These results highlight the potential of using SP as a single drug to maintain HIV-1 suppression once deep latency has been established, in the absence of ART. However, regardless of treatment duration in the latent models tested, transcription remains detectable and once SP treatment is interrupted there is rapid transcriptional rebound to control levels (Fig. 5B). This was not observed with treatment with dCA, where longer treatment periods led to undetectable levels of viral RNA and sustained viral inhibition when treatment was interrupted (41, 43). The reasons for this difference may be two-fold, on one hand since a host component of a transcription factor complex is involved, as soon as XPB is produced again above a certain threshold it can participate and jumpstart transcription from the viral promoter. In fact, the levels of XPB protein become elevated, and remain so for at least 9 days, upon removal of SP (Fig.5C), possibly due to elevated XPB mRNA levels with SP treatment (Fig. 1F). On the other hand, since transcriptional inhibition is not fully complete, the residual level of transcription may preclude epigenetic repressive mark deposition for complete silencing of the promoter.
Future studies will address the benefits of combining SP treatment with other transcriptional inhibitors, such as dCA.

The RNAPII CTD tail contains 52 repeats of the heptad Y₁S₂P₃T₄S₅P₆S₇ that serves as a hotspot for post-translational modification to fine-tune transcription (66, 74–76). Hypophosphorylated RNAPII is recruited to the promoter and is primed for activation by phosphorylation of Ser7 by the CDK7 subunit of TFIIH. Additional phosphorylation of Ser5 by CDK7 activates RNAPII to initiate transcription and escape the promoter, as such pSer5 levels are highest at the TSS but decrease toward the end of genes. Promoter-proximal pausing of RNAPII occurs due to repressive factors (DSIF and NELF) and occlusion by Nuc-1. RNAPII pausing is relieved through CDK9 phosphorylation DSIF, NELF and Ser2 of RNAPII CTD, resulting in a pSer2 peak just downstream of the TSS. Further phosphorylation of Ser2 occurs as RNAPII moves along the gene body, mediated by CDK12/13, resulting in increasing pSer2 levels towards the 3’ end of genes in the gene body and is associated with recruitment of RNA processing and splicing factors (67, 68, 77, 78). Spironolactone treatment results in a loss of RNAPII (total, pSer5 and pSer2) occupancy throughout the HIV genome, particularly noticeable upon LRA stimulation (Fig. 6A-C). In unstimulated cells, little RNAPII is recruited to the promoter of either SP or DMSO treated cells, given the low basal HIV expression in these cells. Upon reactivation with prostratin, some RNAPII was still detected at the TSS in SP treated cells, even with the robust loss of XPB. This is not unexpected, since RNAPII is brought to the promoter during PIC formation, prior to TFIIH recruitment (14, 15, 17). However, since HIV transcription depends on the
positive feedback loop driven by Tat, a reduction in elongation would result in a loss in recycling of RNAPII and reduced overall RNAPII occupancy at the promoter. RNAPII was barely observed in SP+ART treated cells downstream from the promoter, compared to robust recruitment in DMSO+ART treated cells upon transcriptional reactivation. This is consistent with the role of TFIIH in initiation and promoter clearance (16, 18, 19). Significantly, changes in RNAPII occupancy (total, pSer5 and pSer2 CTD) were not observed at either the promoter of GAPDH or the ORF of RPL13A (Fig. 6D-F), suggesting that the HIV-1 genome is especially sensitive to perturbation of TFIIH and the reduction in RNAPII recruitment is specific to the HIV-1 genome. This is consistent with our own results (Fig. 8) and previous work which revealed genes highly dependent on NF-κB experience reduced RNAPII recruitment with SP treatment, while other more constitutively expressed genes were not affected (47). NF-κB has been shown to recruit TFIIH to the inactive RNAPII poised at the HIV TSS, to allow CDK7 phosphorylation of RNAPII CTD (53).

TFIIH is a critical general transcription factor, involved in the initiation of transcription most RNAPII-dependent genes, including HIV (14, 15, 19, 53, 79). However, XPB has been proposed to be dispensable for RNAPII-mediated transcription (51). Despite SP treatment mediating substantial XPB degradation and moderate loss of other TFIIH components, SP seems well tolerated by cells treated long-term. In addition, SP does not appear to interfere with cell cycle progression, it does not cause significant losses of P-TEFb or cell cycle proteins, and has no effect on phosphorylation of CDK9 (Fig. 1G, 2G, 3, 7). In agreement, our mRNA-seq analysis suggests SP treatment specifically and...
potently inhibits HIV expression, while more modestly affecting a subset of cellular genes (Fig. 8). We cannot exclude the possibility that HIV transcription is inhibited indirectly through SP-mediated effects on cellular proteins, since GSEA revealed modest reduction in genes involved in the late phase of the HIV life cycle (Fig. 8B). However, SP did not cause obvious changes in the mRNA expression (TPM count data) of RNA processing genes (capping, cleavage, splicing or export) or RNAPII-related transcription factors (TFIIH, P-TEFb, super-elongation complex, NELF or DSIF) that could have potentially explained the potent downregulation of HIV mRNA expression (Fig. 8C). Intriguingly, histone and chromatin related genes (DNA packaging) were among the most upregulated genes upon SP treatment (Fig. 8B-C). However, these changes are probably not significant, since no changes in cell cycle progression were observed (Fig. 7).

Despite a ~95% reduction in XPB levels, and between 20 and 60% reduction in some other components of TFIIH with 10 µM SP treatment (Fig. 7), we hypothesize there is sufficient amounts of this complex to support basal transcription. Activation dependent genes, such as cytokines and HIV, which require recruitment of large amounts of TFIIH may be more susceptible to XPB loss (47). These results are not unexpected and are consistent with previous reports showing SP treatment does not globally reduce transcription, but rather more selectively inhibits HIV and NF-κB-dependent transcription (47, 48, 51). Interestingly, mRNA-seq differential expression analysis revealed significant downregulation of MYC and MYC-target genes (Fig. 8B). This is consistent with the known role of XPB regulating c-MYC expression through FUSE binding protein (FBP) and the FBP Interacting Repressor (FIR) which bind to the
Far Upstream Sequence Element (FUSE) (80, 81). FBP/FIR act in response to cellular signals to control RNAPII pausing and release through interactions with the XPB subunit of TFIIH to regulate MYC expression (82, 83). It is proposed that FUSE and FIR binding to TFIIH regulates activation-dependent, but not basal MYC expression (82). The level of TFIIH in cells is tightly regulated and correlates with transcriptional activity (84). Thus, we expect that inducible genes that become transcriptionally very active upon stimulation may be more susceptible to XPB degradation than those transcribed at a far lower rate.

Further studies are needed to determine the full extent by which SP treatment inhibits HIV transcription, directly via XPB degradation or indirectly via other altered cellular genes, and the mechanisms behind the increased susceptibility of HIV to SP treatment, compared to the majority of cellular genes (51).

Although SP has been very useful tool to tease out the role of XPB in transcription, it will take some additional monitoring for it to be explored for block-and-lock approaches in the clinic. The concentrations of SP needed for maximal XPB degradation and HIV-1 inhibition (10 µM) is well above the peak serum concentrations reached in healthy volunteers administered 100 mg SP daily for 15 days of around 0.19 µM. The area under the curve (AUC) at day 15, reflecting the actual body exposure to the drug was 0.55 µM, which would result in suboptimal XPB degradation (Fig.1B and 2B) (85). However, SP is used to treat women experiencing hair loss at 200 mg daily without negative effects and transgender women take up to 400 mg daily pre-surgery (86, 87). Additionally, the FDA has approved a four-week treatment of 400 mg daily SP to
diagnose hyperaldosteronism (88). The most common side effects reported at high
doses of SP are gynecomastia, and the more serious hyperkalemia, which requires
monitoring (89). XPB is also involved in nucleotide excision repair and has been
proposed as a means to sensitize cells to platinum-based cancer therapies (46). The
FDA noted that rats treated with 500 mg/kg/day (about 25 times the human
recommended daily dose of 200 mg per day) had an increase in occurrence of benign
tumors. The risk of treating individuals with a dose of SP high enough to degrade XPB
would need to be assessed, and whether or not these side effects will be a major
drawback for clinical testing remains to be seen. SP has, however, great potential to be
used in combination with other therapies, given its very quick effects on HIV. One could
foresee the initial use of high doses of SP to reduce HIV-1 transcription to or below the
level of detection, at which point SP doses could be reduced and another inhibitor, such
as a Tat inhibitor, could be introduced to bring about a state of “deep latency”, from
which rebound would be very difficult to occur. Future studies will investigate this
combination therapy. Furthermore, combination treatments may allow the use of
reduced dosages.

Altogether we showed here that targeting a host component of a transcription
factor complex, XPB, reduces HIV-1 transcription and reactivation from latency without
obvious adverse effects on cellular transcription. We show that SP acts additively with
ART to reduce HIV-1 transcription and block reactivation from latency upon stimulation
with LRAs. Even given some concerns with the high doses of SP required for XPB
degradation in vivo, our results warrant the exploration of SP as a therapeutic in “block-
and-block” approaches for a functional cure.
MATERIALS AND METHODS

Cell lines and cell culture. OM-10.1 and ACH-2 cells were obtained through the NIH AIDS Reagent Program (from Dr. Butera, # 1319 and Dr. Folks, # 349 respectively). Cells were maintained in RPMI 1640 (Gibco) supplemented with 2.0 mM L-glutamine/100 U/ml penicillin/100 μg/ml streptomycin (Gibco) and 10% heat-inactivated FBS (Atlas Biologicals, catalog no. FS-0500-AD) (complete RPMI) and cultured at 37°C and 5% CO2. Cells were passaged every three days and media was replaced with the indicated concentrations of SP, EPL or DMSO and an ART cocktail (200 nM Lamivudine (AIDS Reagent), 200 nM raltegravir (Selleckchem, MK-0518), 100 nM efavirenz (AIDS Reagent)). SP was purchased from Sigma-Aldrich (# 1619006), dissolved in DMSO (Fisher Scientific, # BP231-100). EPL was purchased from Sigma-Aldrich (# E6657-10MG) and dissolved in DMSO. Cell concentration and viability was measured using the TC20 automated cell counter (Bio-Rad, # 1450102) and trypan blue staining.

Infection of Hut78 cells with SIVmac239. Hut78 cells were infected as previously described (90). Briefly, cells were infected overnight with SIVmac239. Cells were then washed with phosphate buffer saline, split into 3 flasks and treated with DMSO, EPL or SP (10 μM) for 12 days. SIV replication was assessed every 3 days post-infection, by measuring the viral capsid in the supernatant with p27 ELISA (Advances Bioscience Laboratories, # 5436).
**Determination of SP half-life in cell culture.** Stability of SP was evaluated in cell culture using an ABSciex 5500 mass spectrometer run in multiple reaction monitoring mode. Cells were treated with 10 µM SP (with or without ART) and the concentration of SP was evaluated before and after 72 h incubation, at multiple time points. Cells were resuspended and treated with 2-times v:v acetonitrile to lyse the cells, precipitate cellular protein, and inactivate the virus. Samples were filtered through a 0.2 micron filter plate prior to injection onto the LC-MS/MS. LC conditions used a Thermo Betasil C18 5µ, 50x2.1mm column with a linear gradient of A: water + 0.1% formic acid and B: acetonitrile with 0.1% formic acid (10%B from 0-5 min, 90%B at 2-3 min, 10%B at 4-6 min). Detection of SP used the mass transition of 417.3à341. Half-life was calculated by plotting the natural log of the percent remaining compound verses time where T1/2 = \( \frac{\ln(2)}{\text{slope of the linear regression}} \).

**p24 ELISA.** The amount of HIV p24 capsid protein produced in the supernatant of cultured cells was quantified using the antigen capture assay kit from Advanced BioScience Laboratories, Inc. (# 5447), and performed according to manufacturer’s protocol.

**MTT Cell Proliferation assay.** The viability and proliferation of cells treated with increasing concentrations of SP and EPL were measured using the MTT assay according to the manufacturer’s protocol (ATCC, # 30-1010K). Cells were cultured in 96-well plates (in triplicate per drug concentration) for 72 h prior to addition of the MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide).
Western blots for OM-10.1, ACH-2 and HUT-78 cells. Cells were collected, washed and lysed with a 20 mM HEPES [pH 8.0], 100 mM KCl, 0.2 mM EDTA, 5 mM β-mercaptoethanol, 0.1% IGEPAL CA-630, 10% glycerol, and supplemented with complete EDTA-free protease inhibitor cocktail (Roche, # 4693132001) on ice for 10 min. For pSer175 and pThr186 CDK9 Western blots we added phosphatase inhibitor cocktail 3 (Sigma-Aldrich, # P0044-1ML). Protein concentration was determined using the Bio-Rad Protein Assay Dye (# 50000006). Equal amounts of total protein extract were loaded, alongside the Precision Plus Protein™ All Blue protein standards (Bio-Rad, # 1610373) onto a pre-cast 4 – 20% gradient stain-free protein gel (Bio-Rad, # 4568094). Proteins were then transferred to a nitrocellulose membrane using the Bio-Rad Trans-Blot® TurboTM system (# 1704270). Membranes were blocked with 5% milk and probed with the following antibodies: anti-XPB (Sigma-Aldrich, # X0879, diluted 1:2000), anti-XPD (Cell Signaling Technology, # 11963S, diluted 1:1000), anti-CDK7 (Santa Cruz, sc-7344, diluted 1:500), Cyclin H (Cell Signaling Technology, # 2927S, diluted 1:1000), p62 (Santa Cruz, sc-25329, diluted 1:500), Cyclin A2 (Cell Signaling Technology, # 4656S, diluted 1:1000), Cyclin E1 (Cell Signaling Technology, # 4129S, diluted 1:500), CDK2 (Cell Signaling Technology, # 25465S, diluted 1:1000), CDK9 (Cell Signaling Technology, # 2316S, diluted 1:1000), pThr186-CDK9 (Cell Signaling Technology, # 2549S), pSer175-CDK9 (kind gift from Jonathan Karn), β-tubulin (proteintech, # 66240-1-IG, diluted 1:10,000) and GAPDH (Santa Cruz, sc-32233, diluted 1:1000) in 3% BSA (or 5% milk for the β-tubulin antibody). Secondary antibodies were anti-mouse (GE Healthcare, # NA931-1ML) diluted 1:10,000 or anti-rabbit (Sigma-
Aldrich, catalog no. A0545), diluted 1:15,000, both conjugated to horseradish peroxidase. Bands were visualized using the Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare, # RPN2236) and imaged on the Bio-Rad ChemiDoc XRS+ System.

**Quantitative PCR of cell-associated RNA.** Total RNA was extracted from cells using RNeasy kit (Qiagen, # 74106). RNA was DNase treated using the TURBO DNA-free™ kit (Invitrogen, # AM1907). cDNA was synthesized using random hexamer primers and SuperScript III First Strand Synthesis kit (Invitrogen, # 18080051). qPCR was performed using SensiFAST™ SYBR ® No-ROX Kit (Bioline, # BIO-98020). Samples were run in duplicate or triplicate. The mRNA expression was normalized to RPL13A mRNA expression and the relative abundance was calculated ($\Delta\Delta Ct$).

**qPCR primers**

RPL13A primers were purchased from Bio-Rad, PrimePCR SYBR Green Assay:

GAATGGCAGACTTGGAGACTTC, GTF2H3-R: GCAAAGTTTCTGTATGTTGACCC,
GTF2H4-F: ACCCATTTCGCCAGAAC, GTF2H4-R:
CGCGTACTTGCTCAAGGGA, GTF2H5-F: AAGACATTGATGACACTCAGTC,
GTF2H5-R: GGGAAAAAGCATTTTGGTCCATT, MNAT1-F:
GGTTGCCCTCGGTGAAGAC, MNAT1-R: AGTTGCTTTTCTGAGTGGAGT,
AllHIVmRNA-F: TTGCTCAATGCCACAGCCAT, AllHIVmRNA-R:
TTTGACCACTTGCCACCCAT, HIV early gag-F: GCGACTGTTGAGTACGCCAA, HIV
early gag-R: CCCCTGGCCTTAACCAGAATTT.

**ChIP qPCR primers**

123-F: CCCTGATTGGCAGAACTACACAC, 123-R:
TCTACCTTATCTGGCTCAACTGGT, 326-F: GACAGCCGCCTAGCATTTCAT, 326-R:
CCACGCCTCCCTGGAAAGT, 412-F: CGAGAGCTGCATCCGGAGTACT, 412-R:
GAGGCTTAACGAGGTTCC, 1097-F: GCAGTCCCTATTTGTGTGCATCAA, 1097-
R: CCTGTGTCAGCTGCTGCTTG, 1477-F: CCATCAATGAGGAAGCTGCAGAA, 1477-
R: GGTGGATTATGTGTCATCCATCCT, 3582-F: CAGAAATACAGAAGCAGGGCCA,
3582-R: GTGTGGGCACCCTTCATTCTT, 6352-F: GAGCAGAAGACAGTGGCAATGA,
6352-R: CACAGGTACCCCATAATAGACTGTG, 8885-F:
CCTGCTGTAAGGGAAAGAATGAGAC, 8885-R: CACCTCTTCTCCTTGTGCT,
GAPDH-F: CCTCACGTATTCCCCCAGGTTTA, GAPDH-R:
AGCCACACCATCCTAGTTCCT.
Cell cycle stage analysis. OM-10.1 cells were treated long-term (80 to 100 days) with ART and 10 µM SP, 10 µM EPL or DMSO, being split and treated every 72 h. After 72 h of incubation, 1 x10^6 cells were collected per condition (in triplicate) for cell cycle analysis. All centrifugation steps were performed at 500 x g for 5 min. Fixation: Cells were washed in 1X DPBS (Gibco, # 14190-250) and then fixed in 66% ice cold ethanol, on ice, for at least 2 h or stored at 4 °C until the next day. Staining: Fixed cells were equilibrated to room temperature, resuspended and pelleted. Fixing solution was aspirated and cells were washed with 1X DPBS. The pellet was resuspended in 0.5 ml of FxCycle PI/RNase staining solution (Invitrogen, # F10797) and stained for 15-30 min at RT, protected from light. Cells were acquired on a BD LSRII flow cytometer using the 561nm laser with the 617/25 band pass filter.

Transduction of OM-10.1 cells. The Mission shRNAs targeting ERCC3 and GFP in the pLKO.1-puro plasmid were purchased from Sigma-Aldrich (SHCLNG: TRCN0000359264 and SHC204 respectively). First, lentiviral vectors were prepared by transient transfection of 293T cells, with the shRNA vector and packaging plasmids pMD2.g and psPAX2 (gifts from Didier Trono, Addgene plasmid # 12259 and # 12260) at a molar ratio of 2:1:1 respectively. Transfections were performed using TransIT-LT1 transfection reagent (Mirus Bio LLC, # MIR 2305) as per manufacturer’s instructions. Lentiviral virus-like particles (VLPs) were collected and filtered through a 0.45 µm filter, to remove cellular debris, at 48 and 72 h post-transfection. Filtered VLPs were combined, quantified and stored at -80°C until use. Three days prior to transduction, media was changed on OM-10.1 cells to remove ART, to allow successful transduction.
with the VLPs. OM-10.1 cells were transduced with equal M.O.I.s of lentiviral vectors in T25 flasks as follows: pLKO.1-shGFP, pLKO.1-ERCC3, pLKO.1-shGFP + 1.8 µM SP, and pLKO.1-shGFP + 6.3 µM SP, in the presence of the indicated concentrations of SP. VLPs were added to cells and a non-transduced control was included. Cells were washed after an overnight incubation and ART (+/- the indicated SP concentrations) was added back to the media. Two days later, cells were selected with 1.5 µg/ml puromycin (Gemini Bio-Products, # 400-128P). Cells were maintained in puromycin supplemented media treated with the indicated concentrations of SP every 3 days. Ten days post-puromycin selection cells were harvested for XPB protein analysis by Western blot and RNA expression analysis of ERCC3 and HIV by RT-qPCR. Additionally, supernatant was collected from each transduction for quantification of HIV capsid protein by p24 ELISA. Cells were counted and viability was determined by trypan blue staining, using the TC20 automated cell counter.

**Latent HIV-1 reactivation.** OM-10.1 cells (after 45 days of treatment with ART and 10 µM SP or DMSO) and ACH-2 cells (after 15 days of treatment with ART and 10 µM SP or DMSO) were stimulated (or not) with 1 µM prostratin (Lc Laboratories, # P-4462-1MG), 10 ng/ml TNF-α (Biolegend, # 570104), 1 µM SAHA (Lc Laboratories, # V-8477_1g) or 20 nM PMA (Sigma-Aldrich, # P1585-1MG). This was done in the presence of ART and either 10 µM SP or DMSO. After 8 h, p24 production was measured in the supernatant by ELISA and cells were collected for RNA extraction and RT-qPCR analysis.
J-Lat A1 cells were treated with 160 nM PMA or 1 ng/ml TNF-α for 2 h and then treated overnight with 10 µM SP, EPL or DMSO, after which the mean fluorescence intensity of GFP was measured by flow cytometry. J-Lat 11.1 cells were treated with 8 nM PMA for 2 h following overnight treatment with 10 µM SP, EPL or DMSO.

Isolation, expansion and reactivation of primary CD4+ T cells

Resting CD4+ T cells were isolated from 7 ART-treated, virally suppressed, HIV-1-infected individuals through magnetic negative depletion as previously described (91) and treated with SP (10 µM) or mock (DMSO) for 24 hrs. The fusion inhibitor enfuvitide was supplemented to the cell culture to prevent new rounds of infection. In the final 6 hrs of culture, the cells were treated with PMA (50 ng/mL) and ionomycin (1 µM) to induce maximum ex vivo latency reversal as previously described (64). Cell-associated HIV-1 RNA was extracted using TRizol phase separation and DNase treatment. HIV-1 RNA expression was measured by RT-qPCR as cell-associated polyadenylated HIV-1 levels per million CD4+ T cells (92, 93). Cellular gene expression (POLR2A, Thermo Fisher, # 4331182) was measured as cell-associated polyadenylated POLR2A levels per million CD4+ T cells.

RNA polymerase II ChIP. Three independent treatments of OM-10.1 cells with ART and 10 µM SP or DMSO for ~70 days were stimulated (or not) with 1 µM prostratin for 8 h. Supernatant and cells were collected for p24 ELISA and RT-qPCR analysis respectively and remaining cells were crosslinked with 1% formaldehyde for 10 minutes and quenched by 0.125 M glycine for 5 min at room temperature. Cells were lysed using...
an SDS lysis buffer and lysates were sonicated 16 times for 10 s bursts on ice to generate sheared chromatin of 200 to 400 nucleotides, in the presence of complete EDTA-free protease inhibitor cocktail (Roche, # 4693132001) and phosphatase inhibitor cocktail 3 (Sigma-Aldrich, # P0044-1ML). The protein concentration of the precleared sonicated lysate was determined using the Bradford protein assay. A 4% fraction of each sonicated lysate was reserved for the input control. 4 µg (per condition) of each of the following antibodies, total RNAP II (Millipore, # 05-623), pSer5 RNAPII CTD (Active Motif, # 61986), pSer2 RNAPII CTD (Active Motif, # 61984) or isotype controls, mouse IgG (Invitrogen, # 31903) or rat-IgG (Thermo Fisher Scientific, # 029602) were conjugated to Protein G Dynabeads (Thermo Fisher Scientific, # 10003D) for 20 min, rotating at RT. A total of 500 µg pre-cleared protein lysate was added to the conjugated beads for IP overnight with rotation at 4°C. Dynabeads were washed, using magnetic separation. Samples were then treated (including input samples) with freshly prepared digestion buffer (10 mM Tris-HCl, 1 mM EDTA, 0.5% SDS, 10 µg/ml RNase A (Thermo Scientific, # EN0531)) at 37°C for 30 min. Cross-links were reversed for at least 4 h shaking (1000 rpm) at 65°C with 200 mM NaCl. DNA samples were then treated with proteinase K (Fisher Scientific, # BP1700100) shaking (1000 rpm) at 60°C for 1 h. Dynabeads were removed and DNA was purified using the QIAquick PCR Purification kit (QIAGEN, # 28106). qPCR was performed in 384-well format using SensiFAST™ SYBR® No-ROX Kit (Bioline, # BIO-98020). The average CT value of the IgG only background for each primer was subtracted from the CT value using the HIV-1 primer. The data were then normalized to input values using the following formula:

% of input = [2-\Delta\text{CT}(\text{IP}) – 2-\Delta\text{CT}(\text{IgG})] \times 4.
**mRNA-seq library preparation**

Total RNA was extracted using the RNeasy kit (Qiagen, # 74106). RNA was DNase treated using the TURBO DNA-freeTM kit (Invitrogen, # AM1907). Total RNA quantified on the Qubit 2.0 fluorometer and run on the Agilent 2100 Bioanalyzer RNA pico chip (Agilent Technologies, Santa Clara, CA) for quality assessment. mRNA was selectively isolated from total RNA (500ng) using poly-T oligos attached to magnetic beads according to the manufacturer’s guidelines in the NEBNext poly(A) mRNA magnetic isolation module (Cat. #: E7490, NEB, Ipswich, MA). The library preparation from the enriched mRNA was conducted according to NEBNext Ultra II Directional RNA kit (Cat. # E7760, NEB, Ipswich, MA). Briefly, the enriched mRNA samples were chemically fragmented at 94°C for 15 minutes. The fragmented RNA was random hexamer primed and reverse transcribed to generate the first strand cDNA. The second strand was synthesized after removing the RNA template and incorporating dUTP in place of dTTP. The incorporation of dUTP quenches the second strand during the PCR amplification step later and therefore the strand information was preserved. The purified ds cDNA was end repaired and adenylated at their 3’ ends. A corresponding ‘T’ nucleotide on the adaptors was utilized for ligating the adaptor sequences to the ds cDNA. The adaptor ligated DNA was purified and PCR amplified to incorporate unique barcodes to generate the final libraries. The final libraries were validated on the bioanalyzer DNA chips, pooled equally and loaded onto the NextSeq 500 for sequencing with 2 x 80bp paired-end chemistry.
Read mapping and differential expression analysis

Raw FASTQC files were filtered for read quality using trim-galore version 0.6.1 with the following options: `--clip_R1 5 --clip_R2 5 --trim-n --paired` (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Trimmed reads were aligned to the human transcriptome (GRCh38v100) with the HIV genome added as an additional chromosome (REFSEQ release 202). To align transcripts, salmon version v0.14.1 was used with the `--validateMappings` option (94). Aligned transcriptomes were mapped to genes and differential gene expression was called using tximportv1.16.1 and DESeq2v1.28.1 respectively (95, 96). TPMs were determined using the `countsFromAbundance = "lengthScaledTPM"` option in tximport. All plots were generated in R. GSEAs were computed from the GSEA app v4.1.0 using TPMs as counts and publicly available gene sets current as of October 2020 (71). DESeq2 and TPM data can be found in Supplemental Tables S1-S5.

Statistical analysis. Statistics were performed using GraphPad Prism, and a P value of <0.05 was considered significant for all comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NS unless indicated. Data is presented as the mean of the indicated replicates with error bars indicating the SD. The two-tailed T-test was used where applicable, and a paired T-test was used for reactivation studies to compare stimulated to unstimulated conditions. Comparison of multiple conditions were performed using a two-way analysis ANOVA repeated-measures test (Dunnett or Holm-Sidak).
REFERENCES:


16. Yan C, Dodd T, He Y, Tainer JA, Tsutakawa SE, Ivanov I. 2019. Transcription preinitiation complex structure and dynamics provide insight into genetic...
associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451–462.


61. McKernan LN, Momjian D, Kulkosky J. 2012. Protein kinase C: One pathway


Er J, Lee A, Parsons LM, Quinn LM. MYC function and regulation in flies: how Drosophila has enlightened MYC cancer biology.


**FIGURE LEGENDS**

**Figure 1.** SP treatment inhibits latent HIV-1 transcription in the OM-10.1 cell line model of latency.

(A) OM-10.1 cells were treated with ART and the indicated concentrations of SP for 72 h, after which the amount of HIV capsid was measured in the supernatant by p24 ELISA. The IC$_{50}$ value was calculated using GraphPad Prism. The line represents the mean of three independent experiments, each with three technical replicates. Error bars represent SD.

(B) Cells treated in (A) were collected for Western blot analysis with the indicated antibodies. Protein abundance was calculated by normalization to GAPDH levels and plotted relative to the DMSO control. A representative blot is shown above the quantification of three independent experiments. Error bars represent SD.

(C) OM-10.1 cells were treated with ART and the indicated concentrations of EPL for 72 h and the IC$_{50}$ values calculated as in (A).

(D) Cytotoxicity of SP (red) and EPL (blue) treated cells in OM-10.1 cells treated for 72 h with increasing concentrations of SP was measured using an MTT assay and plotted as a percentage of the DMSO control. Error bars represent SD from three independent experiments.

(E) OM-10.1 cells were split and treated every 72 h in the presence of ART with 10 µM SP (red), EPL (light blue) or vehicle only (DMSO, dark blue). HIV capsid production was quantified by p24 ELISA. The dotted black line at 3 pg/ml represents the limit of detection (l.o.d). This plot is representative of three independent experiments.
(F) Cell associated HIV mRNA levels (red) and ERCC3 (XPB) mRNA levels (dark red) were measured at multiple time points during the long-term treatments of OM-10.1 with 10 µM SP in (D). cDNA was prepared from RNA extracted from cells pellets and qPCR performed with primers in the Nef region. The results were normalized as the number of viral mRNA copies per RPL13A mRNA and plotted relative to the DMSO treated control (blue, set to 100% for each time point). Error bars represent SD from the qPCR.

(G) The number of viable cells per ml of culture (left panel) and percentage viable cells (right panel), respectively, were measured by trypan blue staining and an automated cell counter every 72 h during the long-term treatments of OM-10.1 cells with 10 µM SP, 10 µM EPL or DMSO only.

Figure 2: Tat-TAR independent inhibition of the ACH-2 T cell model of HIV latency and suppression of SIV infection with SP treatment.

(A) ACH-2 cells were treated with ART and the indicated concentrations of SP for 72 h, after which the amount of HIV capsid was measured in the supernatant by p24 ELISA. The IC50 value was calculated using GraphPad Prism. The line represents the mean of three independent experiments, each with three technical replicates. Error bars represent SD.

(B) Cells treated in (A) were collected for Western blot analysis with the indicated antibodies. Protein abundance was calculated by normalization to GAPDH levels and plotted relative to the DMSO control. A representative blot is shown above the quantification of three independent experiments. Error bars represent SD.
(C) ACH-2 cells were treated with ART and the indicated concentrations of EPL for 72 h and the IC_{50} values calculated as in (A).

(D) Cytotoxicity of SP (red) and EPL (blue) treated cells in ACH-2 cells treated for 72 h with increasing concentrations of SP was measured using an MTT assay and plotted as a percentage of the DMSO control. Error bars represent SD from three independent experiments.

(E) ACH-2 cells were split and treated every 72 h in the presence of ART with 10 µM SP (red), EPL (light blue) or vehicle only (DMSO, dark blue). HIV capsid production was quantified by p24 ELISA. The dotted black line at 3 pg/ml represents the limit of detection (l.o.d). This plot is representative of three independent experiments.

(F) Cell associated HIV mRNA levels (red) and ERCC3 (XPB) mRNA levels (dark red) were measured at multiple time points during the long-term treatments of ACH-2 cells with 10 µM SP in (D). cDNA was prepared from RNA extracted from cells pellets and qPCR performed with primers in the Nef region. The results were normalized as the number of viral mRNA copies per RPL13A mRNA and plotted relative to the DMSO treated control (blue, set to 100% for each time point). Error bars represent SD from the qPCR.

(G) The number of viable cells per ml of culture (left panel) and percentage viable cells (right panel), respectively, were measured by trypan blue staining and an automated cell counter every 72 h during the long-term treatments of ACH-2 cells with 10 µM SP, 10 µM EPL or DMSO only.

(H) HUT-78 cells were infected with SIV239 in the presence of 10 µM SP or 10 µM EPL (or vehicle only, DMSO). Capsid production was monitored over time by p27 ELISA.
Inset is a representative Western blot of XPB protein expression 12 days post infection, the housekeeping gene GAPDH is included as a loading control. (I) Viability of the HUT-78 cells in (H) was measured by trypan blue staining using an automated cell counter. Error bars represent SD of two independent experiments.

Figure 3. shRNA knockdown of the XPB gene, ERCC3, results in similar levels of HIV-1 inhibition in OM-10.1 cells.

OM-10.1 cells were transduced with pLKO.1 puro lentiviral vector expressing either a control shRNA targeting GFP mRNA or an ERCC3 (XPB) shRNA. shGFP transduced cells were also treated with 1.8 µM (IC_{50}), 6.3 µM(IC_{90}) and 10 µM SP. After 10 days of puromycin selection in the presence of ART and DMSO or indicated concentrations of SP cells were harvested for Western blot, p24 ELISA and RT-qPCR analysis.

(A) Quantification of the XPB Western blots from three independent experiments. XPB expression was normalized to β-tubulin expression and plotted as a percentage of the shGFP control.

(B) ERCC3 (XPB) mRNA levels were measured by synthesizing cDNA from cell-associated RNA from transduced cells followed by RT-qPCR. Expression was normalized to RPL13A levels and plotted relative to the shGFP control.

(C) The number of viable cells (left) and percentage of viable cells (right) were determined using trypan blue staining and an automated hemocytometer.

(D) Cell associated HIV mRNA levels were quantified by RT-qPCR and normalized to RPL13A expression. Levels were plotted relative to the shGFP control.
The amount of HIV p24 capsid protein released into the supernatant of transduced OM-10.1 cells were measured by p24 ELISA.

(F) Left panel: A representative Western blot of indicated proteins, from 3 independent experiments. The housekeeping genes GAPDH and β-Tubulin were included as loading controls. Right panel: Quantification of the XPD, CDK7 and Cyclin H Western blots, respectively, from three independent experiments. Protein expression was normalized to the respective housekeeping gene expression and plotted as a percentage relative to the shGFP control.

Error bars represent the SD from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. ****P<0.0001. NS unless indicated. One-way ANOVA followed by the Dunnett multiple comparisons test.

**Figure 4. SP treatment blocks HIV reactivation.**

(A) OM-10.1 cells were treated for 93 days with ART and 10 µM SP or DMSO. Every three days the cells were split, treated and harvested for Western blot, p24 ELISA and RNA analysis. The amount of p24 capsid released into the supernatant of each culture was measured by p24 ELISA every three days.

(B) ACH-2 cells were treated for 15 days with ART and 10 µM SP or DMSO and treated as for OM-10.1 cells above (A).

(C) After 45 days of treatment, OM-10.1 cells from (shown in A) were set aside from each long-term treatment with ART and 10 µM SP (red) or DMSO (blue) and were stimulated with the indicated concentrations of LRAs for 8 h. The amount of cell...
associated HIV mRNA was determined by RT-qPCR, normalized to RPL13A levels and plotted relative to the unstimulated DMSO control.

(D) The same was done on day 15 of long-term ACH-2 treatments with ART and 10 µM SP or DMSO (shown in B).

(E) Resting CD4+ T cells from 18 ART-treated, virally suppressed HIV-1 infected individuals were isolated from whole PBMCs. Patients had to have been on ART for > 1 year with no blips in viral load in the past 6 months. Cells were treated with SP for 24 h in the presence of the fusion inhibitor, T20, to prevent new rounds of infection. In the final 6 h of treatment, cells were subjected to stimulation with PMA + ionomycin. The amount of HIV-1 RNA was measured per million cells.

(F) The amount of POLR2A mRNA was measured as in (E).

The limit of detection (l.o.d.) is shown by the dotted line at 3.0 pg/ml. Error bars represent the SD from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. ****P<0.0001. NS unless indicated. A paired T-Test was used to compare stimulated to unstimulated for each respective treatment. A Wilcoxon matched-pairs signed rank test was used to calculate the p-values for (E) and (F).

Figure 5. SP treatment of OM-10.1 cells suppresses HIV in the absence of ART, but pre-treatment does not delay rebound upon treatment interruption.

(A) On day 69 of the long-term treatment of OM-10.1 cells with ART and 10 µM SP or DMSO, some cells were set aside and washed to remove ART (indicated by the black arrows) and maintained alongside the treatments with ART. Cells were then treated every three days with either DMSO + ART (dark blue), 10 µM SP + ART (red), DMSO
with no ART (light blue) and 10 µM SP with no ART (orange). The amount of HIV capsid released into the supernatant was monitored over time by p24 ELISA.

(B) On day 78 of the long-term treatment of OM-10.1 cells with ART and 10 µM SP or DMSO, some cells were set aside and washed to remove treatments with DMSO or SP (indicated by the black arrow). Cells were then treated every three days with either DMSO + ART (dark blue), 10 µM SP + ART (red), ART with no DMSO (light blue) and ART with no SP (orange). The amount of HIV capsid released into the supernatant was monitored over time by p24 ELISA.

(C) Cells were collected every three days from when DMSO or SP treatments were stopped (light blue and orange lines) for protein expression analysis by Western blotting. A representative blot of the indicated proteins is shown. The limit of detection (l.o.d.) is shown by the dotted line at 3.0 pg/ml. Error bars represent the SD from three independent experiments.

Figure 6. Treatment of OM-10.1 cells leads to a reduction RNA polymerase II occupancy along the HIV genome.

OM-10.1 cells on ~day 70 from long-term treatments with ART and 10 µM SP or DMSO (Fig. 4A) were set aside and stimulated for 8 h with 1 µM prostratin. Cells were then cross-linked prepared for Chromatin immunoprecipitation (ChIP).

(A) ChIP to total RNAPII was followed by qPCR with primers specific to the indicated regions on the HIV genome (Table S2). The dark blue and red lines represent the distribution of RNAPII on the HIV genome in unstimulated cells. The light blue and orange lines represent the distribution of RNAPII on the HIV genome when cells were
stimulated with 1 µM prostratin for 8 h prior to crosslinking. Data for each point is plotted as a fold enrichment relative to the % of input for the unstimulated DMSO control with the first primer set. Grey asterisks mark significance comparing unstimulated SP treated to unstimulated DMSO treated cells. Black asterisks mark significance comparing stimulated SP treated to stimulated DMSO treated.

(B) As above but using an antibody specific to RNAPII CTD phosphorylated on Ser5.

(C) As above but using an antibody specific to RNAPII CTD phosphorylated on Ser2.

(D) ChIP to total RNAPII was followed by qPCR with primers specific to the GAPDH promoter region or RPL13A ORF. Data for each point is plotted as a fold enrichment relative to the % of input for the unstimulated DMSO control with the first primer set.

(E) As above but using an antibody specific to RNAPII CTD phosphorylated on Ser5.

(F) As above but using an antibody specific to RNAPII CTD phosphorylated on Ser2.

*P < 0.05, **P < 0.005, ***P < 0.0005. NS unless indicated. A two-tailed T-test was performed for the comparison of the different treatment groups in (A)-(C). One-way ANOVA followed by the Dunnett multiple comparisons test was used for (D)-(E). Error bars represent SD from three independent experiments.

Figure 7: Effects of SP treatment on transcriptional machinery and cell cycle progression.

(A) OM-10.1 cells treated for 108, 114 and 123 days with ART and 10 µM SP (red bars) or DMSO (blue bar) (Fig. 1D) were collected for analysis of mRNA expression of the indicated components of TFIIH. cDNA was prepared from cell-associated RNA and qPCR performed. The results were normalized per RPL13A and plotted relative to the
DMSO treated control (set to 100%, dotted line). Error bars represent the SD from three independent timepoints.

(B) Left panel: A representative of three independent Western blots of the indicated proteins from OM-10.1 cells treated 108, 114 and 123 days with ART and DMSO, 10 μM SP or 10 μM EPL. Right panel: Quantification of the Western blots on the left, protein expression of the indicated genes were normalized to the housekeeping gene, GAPDH or β-tubulin, and expressed relative to the corresponding DMSO treated control (set to 100%, dotted line).

(C) Left panel: A representative Western blot of the indicated genes in ACH-2 cells treated for 15 days with ART and 10 μM SP or DMSO only. Right panel: Western blot quantification of three independent experiments. The protein expression levels were determined by quantification of the blots, normalized to the housekeeping gene β-tubulin, and expressed relative to the DMSO treated control (set to 100%, dotted line).

(D) Left panel: A representative Western blot of three independent experiments measuring the protein expression of the indicated genes over time (d0, d3, d6 and d21). OM-10.1 cells were treated with ART + 10 μM SP or DMSO for the indicated number of days before harvesting cells for Western blot. Right panel: Quantification of the Western blots on the left for the indicated proteins, levels were normalized to the housekeeping gene, GAPDH or β-tubulin, and expressed relative to the corresponding DMSO treated control (set to 100%).

(E) OM-10.1 cells were treated with ART + DMSO or 10 μM SP for 24 days after which cells were collected for Western blot analysis of the indicated proteins. Left panel: A representative Western blot of 3 independent experiments. Right panel: Quantification
of the three Western blots, protein expression of the indicated genes were normalized to
the housekeeping gene, GAPDH or β-tubulin, and expressed relative to the
corresponding DMSO treated control (set to 100%).

(F) OM-10.1 cells were treated with ART and either DMSO, 10 µM SP or 10 µM EPL for
~80 days. Cell cycle stage analysis was performed by propidium iodide staining and
flow cytometry 72 h post treatment. Left panel: A representative plot showing the degree
of PI staining under each treatment condition. Right panel: A summary of the % of cells
in the indicated stage of the cell cycle.

Error bars represent the SD from three independent experiments. *P < 0.05, **P < 0.01,
***P < 0.001. ****P<0.0001. NS unless indicated. One-way ANOVA followed by the
Dunnett multiple comparisons test.

Figure 8. Potent inhibition of HIV mRNA expression with limited effects on cellular
transcription.

OM-10.1 cells were treated with ART+DMSO or ART+10 µM SP for 15 days (until HIV
capsid production in supernatant in SP-treated cells stabilized below the limit of
detection by p24 ELISA) followed by an 8 h stimulation (or not) with 1 µM prostratin.
mRNA-seq and differential expression analysis was performed on these cells. Data are
from two biological replicates.

(A) Volcano plots showing differentially expressed genes under the indicated conditions.
HIV encoding genes are colored red and the most significantly differentially expressed
genes are colored blue [pAdj<1e-10 & abs(log2FoldChange)>1 for SP vs DMSO
comparisons (left and right panels), and padj<1e-30 with an abs(log2FoldChange)>2.5
for Stim vs No stim comparisons (middle two panels). The horizontal dotted line
represents a pAdj = 0.05 and the vertical dotted lines a log2FC of 1 and -1. Left panel:
The change in expression of all genes (dots) in SP treated compared to DMSO treated
cells without stimulation. Middle left panel: Differentially expressed genes in DMSO
treated cells stimulated with prostratin compared to unstimulated cells. Middle right
panel: Differentially expressed genes in SP treated cells stimulated with prostratin
compared to unstimulated cells. Right panel: Differentially expressed genes in prostratin
stimulated cells treated with SP compared to DMSO.
(B) GSEA Bubble-Lattice Plot of selected gene sets. The color represents the
normalized enrichment score (NES) indicating the number and differential intensity of
the assessed genes in each indicated pathway. NES > 0: the gene set is enriched in the
SP treated sample (red). NES < 0: the gene set is enriched in the DMSO treated sample
(blue). NS = unstimulated, Stim = prostratin stimulated. The size of the dots indicates
the statistical significance of the enrichment found (log transformed familywise error
rate, -log10 FWER p value). GSEAs were computed from the GSEA app v4.1.0 using
TPMs as counts and publicly available gene sets current as of October 2020 (71).
(D) Heat map of expression levels (transcript per kilobase million (TPM) values) for
selected genes with DMSO or SP treatment, with and without stimulation with prostratin.
Day post treatment stop

- DMSO stop (ART only)
- SP stop (ART only)

A

OM-10.1

- DMSO + ART
- 10 µM SP + ART
- DMSO only
- SP only

B

HIV p24 (pg/ml)

Day

Cyclin H
β-tubulin
CDK7
XPB
XPD
Cyclin H

Day

HIV p24 (pg/ml)

OM-10.1

µ

Downloaded from http://jvi.asm.org/